Zobrazeno 1 - 10
of 69
pro vyhledávání: '"Tangpeerachaikul, A."'
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Poss, Zachary C., Ebmeier, Christopher C., Odell, Aaron T., Tangpeerachaikul, Anupong, Lee, Thomas, Pelish, Henry E., Shair, Matthew D., Dowell, Robin D., Old, William M., Taatjes, Dylan J.
Publikováno v:
In Cell Reports 12 April 2016 15(2):436-450
Autor:
Jessica J. Lin, Henry E. Pelish, Aaron N. Hata, Monika A. Davare, Viola Zhu, Matthew D. Shair, James R. Porter, Nancy E. Kohl, John R. Soglia, Yuting Sun, Scot Mente, Satoshi Yoda, Katelyn S. Nicholson, Clare Keddy, Adam Acker, Linh Nguyen-Phuong, Anthonie J. van der Wekken, D. Ross Camidge, Shirish M. Gadgeel, Sai-Hong Ignatius Ou, Benjamin Besse, Anupong Tangpeerachaikul, Joshua C. Horan, Alexander Drilon
NVL-520 Modeling, Properties, Biochemical Activity, Cellular Activity, and In Vivo Activity
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::179b478fa795d20f06c52f43443d2a80
https://doi.org/10.1158/2159-8290.22542255
https://doi.org/10.1158/2159-8290.22542255
Autor:
Jessica J. Lin, Henry E. Pelish, Aaron N. Hata, Monika A. Davare, Viola Zhu, Matthew D. Shair, James R. Porter, Nancy E. Kohl, John R. Soglia, Yuting Sun, Scot Mente, Satoshi Yoda, Katelyn S. Nicholson, Clare Keddy, Adam Acker, Linh Nguyen-Phuong, Anthonie J. van der Wekken, D. Ross Camidge, Shirish M. Gadgeel, Sai-Hong Ignatius Ou, Benjamin Besse, Anupong Tangpeerachaikul, Joshua C. Horan, Alexander Drilon
ROS1 tyrosine kinase inhibitors (TKI) have been approved (crizotinib and entrectinib) or explored (lorlatinib, taletrectinib, and repotrectinib) for the treatment of ROS1 fusion–positive cancers, although none of them simultaneously address the nee
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::04fc95b4f0ef39c29165338ddd307aa5
https://doi.org/10.1158/2159-8290.c.6549846
https://doi.org/10.1158/2159-8290.c.6549846
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Zachary C. Poss, Christopher C. Ebmeier, Aaron T. Odell, Anupong Tangpeerachaikul, Thomas Lee, Henry E. Pelish, Matthew D. Shair, Robin D. Dowell, William M. Old, Dylan J. Taatjes
Publikováno v:
Cell Reports, Vol 15, Iss 2, Pp 436-450 (2016)
Cortistatin A (CA) is a highly selective inhibitor of the Mediator kinases CDK8 and CDK19. Using CA, we now report a large-scale identification of Mediator kinase substrates in human cells (HCT116). We identified over 16,000 quantified phosphosites i
Externí odkaz:
https://doaj.org/article/5d3ce4cfad3a4795abef5531aa404cc4
Autor:
Alexander Drilon, Joshua C. Horan, Anupong Tangpeerachaikul, Benjamin Besse, Sai-Hong Ignatius Ou, Shirish M. Gadgeel, D. Ross Camidge, Anthonie J. van der Wekken, Linh Nguyen-Phuong, Adam Acker, Clare Keddy, Katelyn S. Nicholson, Satoshi Yoda, Scot Mente, Yuting Sun, John R. Soglia, Nancy E. Kohl, James R. Porter, Matthew D. Shair, Viola Zhu, Monika A. Davare, Aaron N. Hata, Henry E. Pelish, Jessica J. Lin
Publikováno v:
Cancer discovery.
ROS1 tyrosine kinase inhibitors (TKI) have been approved (crizotinib and entrectinib) or explored (lorlatinib, taletrectinib, and repotrectinib) for the treatment of ROS1 fusion–positive cancers, although none of them simultaneously address the nee
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7334032e18993114652aa175371035e9
https://pubmed.ncbi.nlm.nih.gov/36511802
https://pubmed.ncbi.nlm.nih.gov/36511802
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Jii Bum Lee, Mi Ra Yu, Mi Ran Yun, You Won Lee, Seung Yeon Oh, Eun Ji Lee, Anupong Tangpeerachaikul, Henry E. Pelish, Byoung Chul Cho
Publikováno v:
Cancer Research. 83:4022-4022
Introduction: NVL-655 is a brain-penetrant, ALK-selective tyrosine kinase inhibitor (TKI) designed to maintain activity against ALK and ALK mutations that confer resistance to currently approved therapies, and to avoid neurological adverse events and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::35f878a2d31b6a17e1de976118154b85
https://doi.org/10.1158/1538-7445.am2023-4022
https://doi.org/10.1158/1538-7445.am2023-4022
Autor:
Tangpeerachaikul, A., Pelish, H.E.
Publikováno v:
In Annals of Oncology September 2024 35 Supplement 2:S217-S217